Cefotiam

Summary

Cefotiam (CHEMBL1296) is an approved small-molecule antibacterial drug (ATC J01DC07); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC07
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 525.6 Da · C18H23N9O4S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1296
Name	Cefotiam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	43708
ChEBI	CHEBI:355510
ATC	J01DC07
Molecular formula	C18H23N9O4S3
Molecular weight	525.6
InChIKey	QYQDKDWGWDOFFU-IUODEOHRSA-N

SMILES: CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O

IUPAC name: (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Aspil, Cefotiam, J01DC07, cefotiam, CEFOTIAM, CEFOTIAM HYDROCHLORIDE, Cefotiam (hydrochloride)

Parent form; salt/anhydrous children: CHEMBL4303232

Patent coverage: 2,393 distinct patent families (8,274 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,265 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02693951	Not specified	UNKNOWN	Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices
NCT03045783	Not specified	UNKNOWN	Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).